Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment
Andrea Desmond(Massachusetts General Hospital), Leif W. Ellisen(Harvard University), Michele Gabree(Massachusetts General Hospital), Stephen E. Lincoln(Whitehead Institute for Biomedical Research), Kristen M. Shannon(Massachusetts General Hospital), Nadine Tung(Beth Israel Deaconess Medical Center), James M. Ford(Stanford University), Michael J. Anderson(Invitae (United States)), Allison W. Kurian(Stanford University), Nora Horick(Massachusetts General Hospital), Shan Yang(Invitae (United States)), Yuya Kobayashi(Cargill (Netherlands)), Meredith Mills(Cargill (Netherlands))
Cited by 334
Related Papers
MAPMAKER: An interactive computer package for constructing primary genetic linkage maps of experimental and natural populations
|Genomics|1987|6.7k
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
|Cell|2018|1.2k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
|Journal of Clinical Oncology|2010|983